Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 3735 3791 3792 3796
This examiner grants 68% of resolved cases
Christian Y Jang is an examiner in Tech Center 3700 and Art Unit 3735, with 857 resolved cases. The allowance rate is 68.5 percent, and the median days to allowance is 1385. These figures provide a view of the prosecution environment where the 68.5 percent allowance rate is the baseline for the 857 resolved cases. The 1385 days to allowance represents the median timeline for reaching a final grant under this examiner's review.
The interview lift of 21.0 percent is a significant factor for practitioners to consider. This 21.0 percent lift suggests that direct engagement can substantially improve the 68.5 percent base allowance rate. In the context of the 1385 days to allowance, an interview may serve as a tool to overcome rejections and potentially reach a resolution. The data from 857 resolved cases highlights that the 21.0 percent lift is a reliable indicator of the examiner's openness to discussion during the prosecution process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18568253 | Respiration Detection | Non-Final OA | Apple Inc. |
| 18931876 | METHOD, SYSTEM, AND DEVICE FOR MEASURING THERMAL CONDUCTIVITY OF TISSUE | Non-Final OA | UIF (University Industry Foundation), Yonsei University |
| 19015978 | ALARM CHARACTERIZATION FOR ANALYTE MONITORING DEVICES AND SYSTEMS | Non-Final OA | ABBOTT DIABETES CARE INC. |
| 18749352 | ANALYTE SENSORS COMPRISING LEVELING AGENTS | Non-Final OA | ABBOTT DIABETES CARE INC. |
| 18674252 | CONTINUOUS ANALYTE MEASUREMENT SYSTEMS AND SYSTEMS AND METHODS FOR IMPLANTING THEM | Non-Final OA | ABBOTT DIABETES CARE INC. |
| 18652924 | SENSITIVITY CALIBRATION OF IN VIVO SENSORS USED TO MEASURE ANALYTE CONCENTRATION | Non-Final OA | Abbott Diabetes Care Inc. |
| 18512733 | METHOD AND SYSTEM FOR PROVIDING CONTINUOUS CALIBRATION OF IMPLANTABLE ANALYTE SENSORS | Final Rejection | ABBOTT DIABETES CARE INC. |
| 18511003 | SYSTEMS, DEVICES, AND METHODS RELATING TO MEDICATION DOSE GUIDANCE | Final Rejection | ABBOTT DIABETES CARE INC. |
| 18055057 | ANALYTE SENSORS FOR SENSING GLUTAMATE AND METHODS OF USING THE SAME | Final Rejection | Abbott Diabetes Care Inc. |
| 18002995 | System and Method for Detection of Biomolecules in Tissues, Organs, and Extracellular Fluid | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18745010 | Human Gait parameter and Health Information Extraction using Floor-Mounted Geophone Sensors | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18740396 | FAULT DISCRIMINATION AND RESPONSIVE PROCESSING BASED ON DATA AND CONTEXT | Non-Final OA | Dexcom, Inc. |
| 18652491 | MEMBRANE FOR CONTINUOUS ANALYTE SENSORS | Non-Final OA | DexCom, Inc. |
| 18592440 | PARTICLE-CONTAINING MEMBRANE AND PARTICULATE ELECTRODE FOR ANALYTE SENSORS | Non-Final OA | DexCom, Inc. |
| 18241655 | CONTINUOUS ANALYTE SENSOR DEVICES AND METHODS | Final Rejection | DexCom, Inc. |
| 18306074 | USER INTERFACES FOR CONTINUOUS GLUCOSE MONITORING | Final Rejection | Dexcom, Inc. |
| 19020080 | PCLED LIGHT SOURCE AND SWIR SPECTROMETER FOR NONINVASIVE TISSUE GLUCOSE SELF-MONITORING | Non-Final OA | LUMILEDS LLC |
| 17096565 | ADAPTIVE DURATION OF INSULIN ACTION FOR USE IN INSULIN ON BOARD CALCULATIONS | Non-Final OA | INSULET CORPORATION |
| 18108819 | ELECTRODE FOR MEASURING GLUCOSE AND ELECTROCHEMICAL SENSOR INCLUDING THE SAME | Final Rejection | ARKRAY, Inc. |
| 17906613 | METHOD AND COMPUTER PROGRAM FOR CONTROLLING INJECTION OF MEDICINAL FLUID | Non-Final OA | EOFLOW CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy